Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Merck
Colorcon
McKinsey
AstraZeneca

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,351,723

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,351,723 protect, and when does it expire?

Patent 7,351,723 protects PROTONIX IV and is included in one NDA.

Protection for PROTONIX IV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-eight patent family members in forty countries.

Summary for Patent: 7,351,723
Title:Freeze-dried pantoprazole preparation and pantoprazole injection
Abstract:Lyophilized pantoprazole preparations which are obtainable by freeze-drying of an aqueous solution of pantoprazole, ethylenediamine tetraacetic acid and/or a suitable salt thereof, and sodium hydroxide and/or sodium carbonate are disclosed. The preparations have advantageous properties when reconstituted for injection.
Inventor(s): Linder; Rudolf (Constance, DE), Dietrich; Rango (Constance, DE)
Assignee: Nycomed GmbH (Constance, DE)
Application Number:10/855,703
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 7,351,723

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Wyeth Pharms PROTONIX IV pantoprazole sodium INJECTABLE;IV (INFUSION) 020988-001 Mar 22, 2001 AP RX Yes Yes   Request a Trial   Request a Trial Y   Request a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,351,723

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
00125569Nov 22, 2000

International Family Members for US Patent 7,351,723

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 034277   Request a Trial
Argentina 092374   Request a Trial
Austria 381946   Request a Trial
Australia 1604202   Request a Trial
Australia 2002216042   Request a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Boehringer Ingelheim
Harvard Business School
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.